

## OCTOBER

Date	Headline and Source	Link	Summary
1 <sup>st</sup> October	Pfizer gets CDSCO Panel nod to study antimicrobial FDC Avibactam plus Aztreonam Medical Dialogues, October 01, 2024	<a href="#">Pfizer gets CDSCO Panel nod to study antimicrobial FDC Avibactam plus Aztreonam</a>	The drug major Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase 2A clinical study of the antimicrobial drug combination Avibactam 0.5 g plus Aztreonam 1.5 g Powder for Concentrate for Solution for Infusion.
1 <sup>st</sup> October	AstraZeneca aims to accelerate introduction of innovative medicines in India CNBC TV18, October 01, 2024	<a href="#">AstraZeneca aims to accelerate introduction of innovative medicines in India</a>	AstraZeneca aims to accelerate introduction of innovative medicines in India Sanjeev Panchal, Country President and MD of AstraZeneca India also talked about their entry into the rare disease therapy area.
2 <sup>nd</sup> October	CDSCO Panel grants GSK's Protocol Amendment Proposal To Study Belantamab mafodotin Medical Dialogues, October 02, 2024	<a href="#">CDSCO Panel grants GSK's Protocol Amendment Proposal To Study Belantamab mafodotin</a>	This came after GlaxoSmithKline Pharmaceuticals presented protocol amendment 03 dated 25 June 2024 protocol no. 209628. Belantamab mafodotin is a monoclonal antibody conjugated with a cytotoxic agent for the treatment of relapsed and refractory multiple myeloma.
3 <sup>rd</sup> October	Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug Business Standard, October 03, 2024	<a href="#">Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug</a>	Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries. The company has entered into a royaltyfree nonexclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement.
9 <sup>th</sup> October	Pfizer Gets CDSCO Panel Nod to Study PF06823859 Medical Dialogues, October 09, 2024	<a href="#">Pfizer Gets CDSCO Panel Nod to Study PF06823859</a>	The drug major Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the trial for the drug PF06823859 This came after the firm presented phase 3 clinical study protocol no. C0251010 version original, dated 08 April 2024.
9 <sup>th</sup> October	GlaxoSmithKline Pharma to enter oncology market, launch adult vax	<a href="#">GlaxoSmithKline Pharma to enter oncology market, launch adult vax</a>	As the country's second-largest drug MNC with nearly 30 crore prescriptions annually, GSK Pharma plans to enter the oncology market with the launch of two

	The Times of India, October 09, 2024		major high-value therapies, expanding beyond its legacy offerings in general medicine, its managing director, Bhushan Akshikar, told TOI.
10 <sup>th</sup> October	GSK Pharma to expand into oncology, focus on adult vaccines in India The Economic Times, October 10, 2024	<a href="#">GSK Pharma to expand into oncology, focus on adult vaccines in India</a>	GSK Pharma Managing Director Bhushan Akshikar shared the company's transformation with TOI. "We remain rooted in our purpose to bring innovation at scale, and with impact," he told TOI, adding that the company's portfolio has been revamped to align with its global focus as a biopharma company.
12 <sup>th</sup> October	Novo Nordisk bets big on India talent, ai tie-ups The Financial Express, October 12, 2024	<a href="#">Novo Nordisk bets big on India talent, ai tie-ups</a>	Novo Nordisk is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI startups. The moves are part of an expansion of the Danish drugmaker's operations in Bengaluru, which launched 17 years ago.
13 <sup>th</sup> October	Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India The Economic Times, October 13, 2024	<a href="#">Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India</a>	Novo Nordisk, whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI start-ups, a top executive told Reuters.
14 <sup>th</sup> October	CDSCO Panel Approves AstraZeneca s Protocol Amendment Proposal for Tozorakimab Study Medical Dialogues, October 14, 2024	<a href="#">CDSCO Panel Approves AstraZeneca s Protocol Amendment Proposal for Tozorakimab Study</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca's proposal for protocol amendment of the clinical trial titled Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease with a History of Exacerbation.
14 <sup>th</sup> October	Interview- 'Government's policy support is important'; AstraZeneca MD Sanjeev Panchal explains India's business plan Hindi - Business Standard, October 14, 2024	<a href="#">Interview- 'Government's policy support is important'; AstraZeneca MD Sanjeev Panchal explains India's business plan</a>	British pharmaceutical giant AstraZeneca is working on several clinical trials and several cancer-related projects in India. The company is trying to bring in technology to speed up its global product launches. Sanjeev Panchal, Managing Director and Country President, AstraZeneca Pharma India, talks about the company's future plans during an interaction with Shine Jacob in Chennai.
18 <sup>th</sup> October	Bayer launches Bepanthen Skincare Brand in India Express Healthcare, October 18, 2024	<a href="#">Bayer launches Bepanthen Skincare Brand in India</a>	Bayer's Consumer Health Division has launched Bepanthen, a globally recognised skincare brand, in India. The launch coincides with findings from the 2024 Bepanthen Survey on Dry Skin, conducted by Ipsos across seven cities in

			India, revealing a high prevalence of dry skin conditions and a significant knowledge gap among patients regarding management of these conditions.
21 <sup>st</sup> October	AstraZeneca gets CDSCO Panel nod to study Budesonide, Glycopyrronium and Formoterol Fumarate Medical Dialogues, October 21, 2024	<a href="#">AstraZeneca gets CDSCO Panel nod to study Budesonide, Glycopyrronium and Formoterol Fumarate</a>	The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase III clinical study of Budesonide, Glycopyrronium, and Formoterol Fumarate.
22 <sup>nd</sup> October	Health Talk   Need for quick vaccine development to save lives Hindustan Times, October 22, 2024	<a href="#">Health Talk   Need for quick vaccine development to save lives</a>	If a vaccine for SARSCoV2 had been developed within 100 days, an estimated 8.3 million deaths could have been averted, suggests a modelling study published in The Lancet Global Health. The 100 Days Mission is an initiative by The Coalition for Epidemic Preparedness Innovations (CEPI) to cut vaccine development time for new pathogens to 100 days. (Pfizer)
23 <sup>rd</sup> October	CD&R makes Rs 2,983 cr open offer for 26% stake in Sanofi Consumer Healthcare India ET Health World, October 23, 2024	<a href="#">CD&amp;R makes Rs 2,983 cr open offer for 26% stake in Sanofi Consumer Healthcare India</a>	Global investment firm CD&R on Monday announced an open offer to acquire a 26% stake in Sanofi Consumer Healthcare India Ltd for an aggregate of up to Rs 2,983 crore. The development follows Sanofi and Clayton, Dubilier & Rice (CD&R) entering into exclusive negotiations whereby CD&R Group has agreed to acquire a controlling stake in Opella, which holds a 60.4% stake in Sanofi Consumer Healthcare India.
24 <sup>th</sup> October	Novo Nordisk's oral Semaglutide cuts cardiovascular risks by 14 percent, study finds Medical Dialogues, October 24, 2024	<a href="#">Novo Nordisk's oral Semaglutide cuts cardiovascular risks by 14 percent, study finds</a>	Novo Nordisk's announced on Monday that an oral version of its drug semaglutide significantly lowered the risk of cardiovascular events in patients during a late-stage study. The drug, Rybelsus, helped reduce the risk of these events, including cardiovascular death, nonfatal heart attack and stroke, by 14% compared to placebo, meeting the main goal of the trial.
27 <sup>th</sup> October	Johnson & Johnson Gets CDSCO Panel Nod to Study anticancer drug Amivantamab Medical Dialogues, October 27, 2024	<a href="#">Johnson &amp; Johnson Gets CDSCO Panel Nod to Study anticancer drug Amivantamab</a>	The drug major Johnson & Johnson has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct a phase III clinical study of the anticancer drug Amivantamab.

28 <sup>th</sup> October	CDSCO Panel grants Novo Nordisk Protocol Amendment Proposal to study concizumab Medical Dialogues, October 28, 2024	<a href="#">CDSCO Panel grants Novo Nordisk Protocol Amendment Proposal to study concizumab</a>	Recommending to increase the number of subjects from 15 to 35, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by Novo Nordisk to study the efficacy, safety, and pharmacokinetics of concizumab prophylaxis in children below 12 years with hemophilia A or B with or without inhibitors.
29 <sup>th</sup> October	CDSCO Panel Approves Novartis Protocol Amendment Proposal to study-Ribociclib Medical Dialogues, October 29, 2024	<a href="#">CDSCO Panel Approves Novartis Protocol Amendment Proposal to study-Ribociclib</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novartis protocol amendment proposal for the clinical trial protocol titled, A posttrial access rollover study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study.
29 <sup>th</sup> October	Merck and Tinkle Partner to Launch Comic Books Raising Food Safety Awareness for Kids - The CSR Journal The CSR Journal, October 29, 2024	<a href="#">Merck and Tinkle Partner to Launch Comic Books Raising Food Safety Awareness for Kids - The CSR Journal</a>	Merck, a leading science and technology, today launched two engaging comic books in collaboration with Tinkle at Indian Institute of Science, Bengaluru. These books were unveiled in the presence of over 200 students from Government Schools in Bengaluru as part of its campaign which focused on food safety – SafeFoodFirst.
30 <sup>th</sup> October	AstraZeneca Gets CDSCO Panels Nod to study anticancer drug AZD0901 Medical Dialogues, October 30, 2024	<a href="#">AstraZeneca Gets CDSCO Panels Nod to study anticancer drug AZD0901</a>	The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the trial of the anticancer drug AZD0901 powder for solutions for infusion.
30 <sup>th</sup> October	Nagaland H&FW explores collaboration with Novo Nordisk Foundation Morung Express, October 30, 2024	<a href="#">Nagaland H&amp;FW explores collaboration with Novo Nordisk Foundation</a>	The Department of Health & Family Welfare, Nagaland held a consultative meeting with members of Novo Nordisk Foundation (NNF) from Denmark for possible collaboration in various fields of health programmes and education, nursing & medical education, environmental sustainability, food security and nutrition. The meeting was held at HFW Conference Hall, Nagaland Civil Secretariat on October 28.

-----